microRNAs identified in prostate cancer: Correlative studies on response to ionizing radiation

• Main Authors: Maureen Labbé, Christianne Hoey, Jessica Ray, Vincent Potiron, Stéphane Supiot, Stanley K. Liu, Delphine Fradin
• Format: Article
• Language: English
• Published: BMC 2020-03-01
• Series: Molecular Cancer
• Subjects: microRNA; prostate cancer; radiotherapy; radiation resistance; biomarkers
• Online Access: http://link.springer.com/article/10.1186/s12943-020-01186-6

Abstract As the most frequently diagnosed non-skin cancer in men and a leading cause of cancer-related death, understanding the molecular mechanisms that drive treatment resistance in prostate cancer poses a significant clinical need. Radiotherapy is one of the most widely used treatments for prostate cancer, along with surgery, hormone therapy, and chemotherapy. However, inherent radioresistance of tumor cells can reduce local control and ultimately lead to poor patient outcomes, such as recurrence, metastasis and death. The underlying mechanisms of radioresistance have not been fully elucidated, but it has been suggested that miRNAs play a critical role. miRNAs are small non-coding RNAs that regulate gene expression in every signaling pathway of the cell, with one miRNA often having multiple targets. By fine-tuning gene expression, miRNAs are important players in modulating DNA damage response, cell death, tumor aggression and the tumor microenvironment, and can ultimately affect a tumor’s response to radiotherapy. Furthermore, much interest has focused on miRNAs found in biofluids and their potential utility in various clinical applications. In this review, we summarize the current knowledge on miRNA deregulation after irradiation and the associated functional outcomes, with a focus on prostate cancer. In addition, we discuss the utility of circulating miRNAs as non-invasive biomarkers to diagnose, predict response to treatment, and prognosticate patient outcomes.